Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Neuromodulation for Functional Recovery After Stroke (VNS-EARLY)

20. september 2026 oppdatert av: Xuanwu Hospital, Beijing

This study used a multicenter, double-blind, randomized controlled design. The trial protocol was jointly designed by the principal investigator and an executive committee composed of experts in functional neurosurgery, cerebrovascular disease, and rehabilitation medicine. The study enrolled patients in the subacute phase (3-6 months) after ischemic stroke with upper limb motor impairment. All patients were implanted with a vagus nerve stimulation (VNS) device and randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group.

This study used the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity. The primary endpoint was the difference in FMA-UE score between the active VNS group and the control group at the end of 6 weeks of hospital treatment. Secondary endpoints included changes from baseline in FMA-UE score and WMFT score at 90 days, among others. This study evaluates the safety and efficacy of vagus nerve stimulation for improving upper limb motor function in patients in the subacute phase after stroke, ultimately providing clinical evidence for the diagnosis and treatment of this patient population.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

This study uses a multicenter, double-blind, randomized controlled design. Eligible participants all undergo implantation of a VNS device and are randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group. The study hypothesizes that vagus nerve stimulation is effective in improving upper limb motor function in patients in the subacute phase after stroke; that is, a meaningful difference in FMA-UE scores exists between the active VNS group and the control group at the end of 6 weeks of hospital treatment. All enrolled participants undergo implantation of a vagus nerve stimulation device. After preoperative assessment, patients undergo implantation of the vagus nerve stimulation device under general anesthesia. After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). This trial uses the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity, with a pretreatment baseline assessment performed 1 week after implantation. Stimulation testing is performed in 0.1 mA increments in both groups to assess the level at which participants can perceive and tolerate stimulation. Hospital treatment begins on the day after baseline assessment.

Studietype

Intervensjonell

Registrering (Antatt)

100

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Xuesong Bai, Dr.
  • Telefonnummer: 86 18810032664
  • E-post: bxsben@163.com

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. History of unilateral supratentorial ischemic stroke and in the subacute phase (3-6 months);
  2. Age between 18-80 years, both male and female;
  3. FMA-UE score of 20-50 (inclusive);
  4. Ability to communicate, understand, and provide appropriate consent; participant can follow two-step commands;
  5. Right or left upper limb weakness;
  6. Active flexion/extension of the wrist or fingers;
  7. Informed consent signed by the patient or a family member.

Exclusion Criteria:

  1. History of hemorrhagic stroke;
  2. Persistent dysphagia or choking/coughing while eating or drinking;
  3. Medications that, at study initiation, may significantly interfere with the effects of VNS on neurotransmitter systems;
  4. Prior vagus nerve injury, bilateral or unilateral (e.g., injury during carotid endarterectomy);
  5. Severe or more severe depression (Beck Depression Inventory >29);
  6. Candidates unsuitable for device implantation surgery (e.g., history of adverse reaction to anesthesia, deemed unsuitable as a surgical candidate by the surgeon, etc.);
  7. Current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug;
  8. Preexisting neurological or psychiatric disorders before stroke onset that affect assessment of the condition;
  9. Pregnancy, planned pregnancy, or breastfeeding during the study period;
  10. Severe upper limb spasticity (modified Ashworth ≥3);
  11. Severe sensory loss. Sensory loss will be measured using the upper extremity sensory portion of the Fugl-Meyer Assessment. The assessment involves light touch (two items) and proprioception (four items). The maximum score is 12; subjects with a score below 6 will be excluded from the study;
  12. Other conditions that the investigator considers unsuitable for participation or that may pose a significant risk to the patient.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Active VNS group

After implantation, participants randomized to active VNS (0.8 mA) combined with upper limb rehabilitation.

After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). To reduce the risk of participants inferring treatment assignment, participants in both treatment groups receive five stimuli of decreasing intensity at the beginning of each treatment session (starting at 0.8 mA and then decreasing by 0.1 mA at each step), after which treatment is administered according to randomization.

Sham-komparator: Control VNS group

After implantation, participants randomized to control VNS (0 mA) combined with upper limb rehabilitation.

After implantation, participants randomized to Control VNS (0.8 mA) combined with upper limb rehabilitation.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The difference in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores between the active VNS group and the control group at the end of 6 weeks of hospital treatment.
Tidsramme: At the end of 6 weeks of hospital treatment.

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

At the end of 6 weeks of hospital treatment.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinically meaningful improvement in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days (≥6-point improvement in FMA-UE score);
Tidsramme: 90 days

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

90 days
Change from baseline in Wolf Motor Function Test (WMFT) score at 90 days
Tidsramme: 90 days

The WMFT Functional Ability Scale ranges from 0 to 75, with higher scores indicating better upper-extremity function.

90 days
Change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days
Tidsramme: 90 days

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

90 days

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in Stroke Impact Scale (SIS) score at 90 days
Tidsramme: 90 days

The SIS score ranges from 0 to 100, with higher scores indicating better health status and functioning.

90 days
Change from baseline in Stroke-Specific Quality of Life (SS-QOL) score at 90 days
Tidsramme: 90 days

The SS-QOL total score ranges from 49 to 245, with higher scores indicating better quality of life.

90 days
Change from baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index score at 90 days
Tidsramme: 90 days

The EuroQol 5-Dimension 5-Level utility index ranges from -0.391 to 1.000, with higher scores indicating better health-related quality of life.

90 days
Change from baseline in Motor Activity Log (MAL) score at 90 days
Tidsramme: 90 days

Each MAL subscale ranges from 0 to 5, with higher scores indicating better real-world use and movement quality of the affected upper extremity.

90 days
Change from baseline in Beck Depression Inventory (BDI) total score at 90 days
Tidsramme: 90 days

The BDI total score ranges from 0 to 63, with higher scores indicating more severe depressive symptoms and therefore a worse outcome.

90 days
Adverse events: adverse events occurring during the study period (including the surgical procedure);
Tidsramme: From study enrollment through the Day 90 follow-up visit, including the perioperative period.
From study enrollment through the Day 90 follow-up visit, including the perioperative period.
Device complications: any unexpected adverse reactions of the device
Tidsramme: From device implantation through the Day 90 follow-up visit.
From device implantation through the Day 90 follow-up visit.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

  • 1. 王拥军, et al., 中国卒中报告2019(中文版)(1). 中国卒中杂志, 2020. 15(10): p. 1037-1043. 2. Nakayama, H., et al., Recovery of upper extremity function in stroke patients: The Copenhage n stroke study. Archives of Physical Medicine and Rehabilitation. 75(4): p. 394-398. 3. Opara, J.A. and K. Jaracz, Quality of life of post-stroke patients and their caregivers. J Med Life, 2010. 3(3): p. 216-20. 4. Butt, M.F., et al., The anatomical basis for transcutaneous auricular vagus nerve stimulation. J Anat, 2020. 236(4): p. 588-611. 5. van der Meij, A. and M.J.H. Wermer, Vagus nerve stimulation: a potential new treatment for ischaemic strok e. Lancet (London, England). 397(10284): p. 1520-1521. 6. Ay, I., et al., Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Isch emic Injury in Rats. Brain stimulation. 9(2): p. 166-73. 7. Kimberley, T.J., et al., Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Ch ronic Stroke. Stroke. 49(11): p. 2789-2792. 8. Dawson, J., et al., Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke, 2016. 47(1): p. 143-50. 9. Dawson, J., et al., Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet, 2021. 397(10284): p. 1545-1553. 10. Grefkes, C. and G.R. Fink, Recovery from stroke: current concepts and future perspectives. Neurological Research and Practice, 2020. 2(1): p. 17.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

30. oktober 2026

Primær fullføring (Antatt)

1. september 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

13. september 2026

Først innsendt som oppfylte QC-kriteriene

20. september 2026

Først lagt ut (Faktiske)

25. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

The VNS-EARLY Steering Committee will consider on a case-by-case basis requests for data sharing.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere